US Stock MarketDetailed Quotes
ZNTL Zentalis Pharmaceuticals
- 11.060
- +0.075+0.68%
Close Apr 26 16:00 ET
- 11.060
- 0.0000.00%
Post 16:20 ET
784.82MMarket Cap-2474P/E (TTM)
11.230High10.770Low474.11KVolume11.100Open10.985Pre Close5.23MTurnover0.94%Turnover RatioLossP/E (Static)70.96MShares31.46052wk High1.79P/B556.89MFloat Cap9.56052wk Low--Dividend TTM50.35MShs Float87.190Historical High--Div YieldTTM4.19%Amplitude9.560Historical Low11.032Avg Price1Lot Size
Zentalis Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -26.91%-207.82M | -8.76%-40.6M | -16.46%-38.67M | -84.24%-79.28M | 1.82%-49.28M | -6.27%-163.75M | -0.83%-37.33M | 0.87%-33.2M | 6.69%-43.03M | -33.97%-50.2M |
| Net income from continuing operations | -23.28%-292.31M | -10.83%-60.94M | -1.91%-55.54M | -64.59%-112.56M | -6.79%-63.26M | -42.76%-237.11M | -9.76%-54.98M | -419.44%-54.5M | -24.21%-68.39M | -17.43%-59.24M |
| Operating gains losses | 0.50%16.42M | -94.10%410K | --0 | 62.13%8.75M | 314.79%7.26M | 133.98%16.34M | 279.36%6.95M | 104.50%2.25M | --5.4M | 11,573.33%1.75M |
| Depreciation and amortization | -2.59%1.39M | -6.13%337K | -7.20%348K | -1.15%344K | 4.65%360K | 162.13%1.43M | 71.77%359K | 173.72%375K | 192.44%348K | 335.44%344K |
| Deferred tax | -10.92%-853K | --0 | --0 | -1,121.62%-756K | -31.08%-97K | 69.36%-769K | -1,502.08%-769K | --0 | --74K | ---74K |
| Other non cash items | --15.05M | --0 | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | -55.75%5.86M | 157.80%10.27M | -50.37%4.78M | -277.27%-5.16M | -22.79%-4.02M | -20.19%13.25M | 64.93%3.98M | -23.64%9.63M | 320.51%2.91M | -212.82%-3.27M |
| -Change in prepaid assets | 14.03%-5.68M | 74.64%-479K | -165.59%-1.28M | 59.94%-1.01M | 29.78%-2.92M | -610.43%-6.61M | -369.90%-1.89M | -62.71%1.95M | -15.73%-2.51M | -206.12%-4.15M |
| -Change in payables and accrued expense | -29.68%10.92M | 105.88%10.4M | -1.94%6.33M | -197.10%-4.39M | -182.20%-1.41M | 11.19%15.53M | 205.32%5.05M | -13.65%6.45M | 195.56%4.53M | -115.12%-500K |
| -Change in other working capital | -85.61%623K | -57.42%350K | -122.03%-271K | -73.80%235K | -77.62%309K | 221.46%4.33M | -44.16%822K | 413.78%1.23M | 274.17%897K | 76.60%1.38M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -26.91%-207.82M | -8.76%-40.6M | -16.46%-38.67M | -84.24%-79.28M | 1.82%-49.28M | -6.27%-163.75M | -0.83%-37.33M | 0.87%-33.2M | 6.69%-43.03M | -33.97%-50.2M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 61.06%-44.46M | -253.62%-42.06M | -686.73%-117.45M | 151.32%72.93M | 112.78%42.12M | -530.31%-114.18M | -127.49%-11.89M | 114.15%20.02M | -313.35%-142.1M | 47.09%19.8M |
| Net PPE purchase and sale | 77.12%-583K | -8.13%-173K | 94.52%-91K | -14.75%-319K | --0 | 58.28%-2.55M | 92.70%-160K | 37.62%-1.66M | 66.06%-278K | -3.21%-450K |
| Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | 60.70%-43.88M | -256.97%-41.89M | -641.38%-117.36M | 151.65%73.25M | 108.05%42.12M | -4,928.37%-111.63M | -125.81%-11.73M | 117.42%21.68M | -310.35%-141.82M | 45.72%20.25M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 61.06%-44.46M | -253.62%-42.06M | -686.73%-117.45M | 151.32%72.93M | 112.78%42.12M | -530.31%-114.18M | -127.49%-11.89M | 114.15%20.02M | -313.35%-142.1M | 47.09%19.8M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -9.09%237.3M | 0 | -47.54%309K | 12.97%236.62M | -70.35%373K | 46.23%261.04M | 305.49%49.74M | -99.65%589K | 66,383.23%209.46M | 1.26M |
| Net common stock issuance | -9.09%237.3M | --0 | -47.54%309K | 12.97%236.62M | -70.35%373K | 45.29%261.04M | 270.84%49.74M | -99.65%589K | 299,121.43%209.46M | --1.26M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -9.09%237.3M | --0 | -47.54%309K | 12.97%236.62M | -70.35%373K | 46.23%261.04M | 305.49%49.74M | -99.65%589K | 66,383.23%209.46M | --1.26M |
| Net cash flow | ||||||||||
| Beginning cash position | -26.98%45.7M | 150.96%113.38M | 365.96%269.19M | 16.34%38.91M | -26.98%45.7M | 11.22%62.58M | 2.51%45.18M | 10.18%57.77M | 3.66%33.44M | 11.22%62.58M |
| Current changes in cash | 11.32%-14.98M | -16,057.34%-82.66M | -1,137.35%-155.81M | 846.56%230.28M | 76.70%-6.79M | -367.51%-16.89M | -97.20%518K | -50.57%-12.59M | 20.59%24.33M | -21.37%-29.14M |
| End cash Position | -32.78%30.72M | -32.78%30.72M | 150.96%113.38M | 365.96%269.19M | 16.34%38.91M | -26.98%45.7M | -26.98%45.7M | 2.51%45.18M | 10.18%57.77M | 3.66%33.44M |
| Free cash flow | -25.32%-208.41M | -8.76%-40.77M | -11.18%-38.76M | -83.80%-79.59M | 2.69%-49.28M | -3.81%-166.3M | 4.39%-37.49M | 3.57%-34.86M | 7.73%-43.31M | -33.61%-50.65M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg